Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities

Azenta (Nasdaq: AZTA) acquired UK Biocentre Limited to expand biorepository and sample-management capabilities across Europe.

Rhea-AI Summary

Azenta (Nasdaq: AZTA) acquired UK Biocentre Limited to expand biorepository and sample-management capabilities across Europe.

The deal consideration was GBP 20.5 million (net of cash, including up to GBP 1.8 million contingent). UK Biocentre had ~GBP 15.3 million revenue for the 12 months ended Sept 30, 2025. Azenta expects ~35bps dilution to 2026 Adjusted EBITDA margin and anticipates accretion to 2027–2028 organic revenue and margin targets. Azenta plans to deploy its 16-million-sample BioArc™ Ultra later in the year. A transaction webcast is scheduled for March 10, 2026.

Positive

• Transaction value of GBP 20.5 million including contingent consideration
• Pro forma revenue contribution of approximately GBP 15.3 million (12 months to Sept 30, 2025)
• European hub established to expand sample storage and processing capabilities across the region
• Capacity expansion via deployment of 16-million-sample BioArc Ultra later in 2026

Negative

• None.

Argus Mar 4 session

+2.40% close to close Open Argus

Details

News Market Reaction – AZTA

On Mar 4, the day this news came out, AZTA closed 2.40% above the previous close.

Data tracked by StockTitan Argus for the Mar 4 session.

Market Context

This announcement details Azenta’s acquisition of UK Biocentre for GBP 20.5 million, adding a Europe...

Analysis

This announcement details Azenta’s acquisition of UK Biocentre for GBP 20.5 million, adding a European hub that generated GBP 15.3 million in revenue over the prior twelve months. Management expects about 35 bps dilution to 2026 Adjusted EBITDA margin but views the deal as supportive to 2027–2028 organic growth and margin expansion targets. In context of recent portfolio reshaping and flat quarterly revenue, investors may track integration progress, realized synergies, and updated margin guidance on the March 10, 2026 call.

Key Figures

Acquisition consideration: GBP 20.5 million Contingent consideration: Up to GBP 1.8 million UK Biocentre revenue: GBP 15.3 million +5 more

Acquisition consideration

GBP 20.5 million

Total consideration for UK Biocentre, net of cash

Contingent consideration

Up to GBP 1.8 million

Earn-out tied to completion of certain milestones

UK Biocentre revenue

GBP 15.3 million

Revenue over twelve months ending fiscal Sept 30, 2025

EBITDA margin impact

35 bps dilutive

Expected impact on 2026 Adjusted EBITDA margin

BioArc Ultra capacity

16 million samples

Capacity of BioArc Ultra biorepository system

UK Biocentre founding

2014

Year UK Biocentre was founded

Conference call date

March 10, 2026

Scheduled call to discuss the acquisition

Conference call time

10:00 am Eastern Time

Start time for acquisition conference call

Historical Context

5 past events · Latest: Feb 24

5 events

1. Feb 24

   Conference participation

   24h Move

   -1.1%

   Participation in Raymond James institutional investor conference with webcast access for stakeholders.

2. Feb 09

   Strategic partnership

   24h Move

   +0.6%

   Partnership with Frontier Space to test sample management technologies in space mission.

3. Feb 04

   Earnings and divestiture

   24h Move

   -22.8%

   Flat revenue, margin compression, and detailed plans to sell B Medical Systems.

4. Jan 21

   Earnings call setup

   24h Move

   +1.6%

   Announcement of schedule and access details for fiscal Q1 2026 earnings call.

5. Dec 29

   Business sale agreement

   24h Move

   -0.2%

   Definitive agreement to sell B Medical Systems to streamline portfolio and focus on core areas.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

contingent consideration, adjusted ebitda margin, organic revenue growth, biorepository

4 terms

contingent consideration financial

"inclusive of up to GBP 1.8 million in contingent consideration upon the completion"

Contingent consideration is an additional payment agreed when one company buys another that will be paid later only if specific future targets are met, such as revenue, profit, or regulatory milestones. It matters to investors because it shifts risk between buyer and seller and affects the acquiring company's future cash flow and reported value — like promising a bonus after results are proven.

adjusted ebitda margin financial

"dilutive to 2026 Adjusted EBITDA margin by approximately 35bps and accretive"

Adjusted EBITDA margin shows how much profit a company makes from its core operations, expressed as a percentage of its total revenue, after removing certain one-time or unusual expenses and income. It helps investors understand the company's true earning ability from regular business activities, making it easier to compare performance over time or with other companies. Think of it as measuring the efficiency of a business in turning sales into profits, excluding irregular adjustments.

organic revenue growth financial

"accretive to our 2027 and 2028 organic revenue growth rate and Adjusted EBITDA"

Organic revenue growth is the increase in a company's sales that comes from its existing products and services, without including any gains from acquisitions or selling off parts of the business. It reflects the company’s ability to attract more customers or encourage existing customers to buy more over time. For investors, it indicates the company's underlying strength and efficiency in expanding its core operations.

biorepository medical

"major hub will support our already established biorepository in Griesheim, Germany"

A biorepository is a secure facility that collects, stores and manages biological samples such as blood, tissue and DNA, along with the data about them, much like a library or bank for biological materials. For investors it matters because access to well-curated samples and data can speed drug or diagnostic development, create partnership or licensing opportunities, and represent a tangible scientific asset whose quality and scale can affect a company’s research prospects and potential future revenue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGTON, Mass., March 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquired UK Biocentre Limited, a leading provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom. The total consideration was GBP 20.5 million, net of cash and inclusive of up to GBP 1.8 million in contingent consideration upon the completion of certain milestones.

The acquisition strengthens Azenta's ability to deliver end-to-end lifecycle solutions in the UK, a leading life science research epicenter, while expanding its presence in Europe by establishing the UK Biocentre as a European-wide operational hub to support pharmaceutical, biotechnology, academic, and public health customers across the region. This major hub will support our already established biorepository in Griesheim, Germany with current and new customers benefiting from expanded sample storage automated capabilities, reliable and fully integrated sample management and processing services, and a broader European footprint to support the region. UK Biocentre will continue to operate under its existing name. 

Founded in 2014, UK Biocentre supports large‑scale biomedical, pharmaceutical, and clinical studies, enabling life‑changing research across academic, pharmaceutical, and biotechnology communities. Its high‑quality, automated solutions have made it a trusted partner supporting critical scientific discoveries and population‑scale programs. UK Biocentre generated approximately GBP 15.3 million in revenue over the twelve months ending fiscal September 30, 2025. On a pro forma fiscal-year basis, we expect the acquisition to be dilutive to 2026 Adjusted EBITDA margin by approximately 35bps and accretive to our 2027 and 2028 organic revenue growth rate and Adjusted EBITDA margin expansion expectations underlying our December Investor Day targets.

"The acquisition of UK Biocentre is a strategic step in positioning Azenta at the center of the most critical workflows in the life sciences ecosystem," said John Marotta, President and Chief Executive Officer. "This transaction strengthens our end-to-end sample management solutions platform with deep operational expertise, and enhances our ability to deliver highly scalable, next-generation biorepository capabilities, including the deployment of our 16-million-sample BioArc™ Ultra, which will further expand our automated, high- throughput capacity later this year. It broadens our global footprint, fully aligns with our disciplined capital allocation strategy, and reinforces our leading positioning across the industry."

"Today marks a pivotal moment for UK Biocentre. Joining Azenta brings together two life science organizations united by a shared commitment to scientific excellence, innovation, and world-class sample management," said Dr Tony Cox OBE, Chief Executive Officer of UK Biocentre. "Azenta's global leadership in sample management, biorepository solutions and genomic services gives us the platform to accelerate our growth, strengthen our infrastructure, and future-proof our capabilities at scale. Together, we will expand our reach across Europe and enhance the services we provide to research, industry and academic science. Our mission remains unchanged: to enable and advance life-changing research. With Azenta's expertise and global resources behind us, we are entering an exciting new chapter - delivering even greater impact, resilience and value for our customers and partners."

In connection with the transaction, Deloitte served as exclusive financial advisor to Azenta, and Bird & Bird LLP served as legal counsel.

Conference Call and Webcast:

Azenta will host a conference call and webcast to discuss the transaction on Tuesday, March 10, 2026, at 10:00 am Eastern Time. The call will be broadcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Azenta's website at https://investors.azenta.com/events.
Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available on March 11, 2026.

About UK Biocentre:

UK Biocentre (UKBC) is a leading provider of sample management, sample storage and high-throughput sample processing. UKBC supports and facilitates large-scale studies, enabling life-changing research in the academic, pharmaceutical and biotech communities. UKBC provides end-to-end solutions, from sample collection through to processing, analysis and long-term sample cold storage. https://www.ukbiocentre.com/ 

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934
This press release contains forward‑looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward‑looking statements are based on current assumptions, expectations, and beliefs and include, without limitation, statements regarding, anticipated financial and operational impacts of the transaction, future revenue growth, expected adjusted EBITDA margin performance, strategic benefits, integration plans, and other statements that are not historical facts.

Forward‑looking statements are not guaranteed of future performance, and actual results may differ materially due to a variety of risks and uncertainties. These risks include, but are not limited to: the ability to successfully integrate UK Biocentre's operations; customer acceptance of and demand for the combined companies' offerings; potential disruptions to existing business operations; expected synergies or financial benefits not being realized on the anticipated timeline or at all; changes in market, industry, regulatory, or economic conditions; and other factors described in Azenta's filings with the Securities and Exchange Commission. Forward‑looking statements involve estimates, assumptions, and uncertainties, many of which are beyond the Company's control, and actual outcomes may differ materially from those expressed or implied in such statements.

Forward‑looking statements speak only as of the date of this release. Azenta undertakes no obligation to publicly update or revise any forward‑looking statements, whether as a result of new information, future developments, or otherwise, except as required by law.

INVESTOR CONTACT for Azenta Life Sciences:
Yvonne Perron
Vice President, Financial Planning & Analysis and Investor Relations 
ir@azenta.com 

Maria Isabel Cuartas
Manager Investor Relations
ir@azenta.com 

MEDIA CONTACT for UK Biocentre
Helen Embleton
helen@ambitiouspr.co.uk

View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-completes-strategic-acquisition-of-uk-biocentre-limited-to-expand-biorepository-capabilities-302703963.html

SOURCE Azenta

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Azenta (AZTA) pay to acquire UK Biocentre and what are the payment terms?

Azenta paid GBP 20.5 million in total consideration, net of cash, including up to GBP 1.8 million of contingent consideration. According to Azenta, the contingent portion is payable upon completion of specified milestones tied to the acquisition.

What revenue did UK Biocentre contribute to Azenta (AZTA) on a trailing basis?

UK Biocentre generated approximately GBP 15.3 million in revenue for the twelve months ending Sept 30, 2025. According to Azenta, this revenue will be reflected on a pro forma fiscal-year basis for integration planning and reporting.

What is the expected near-term margin impact to Azenta (AZTA) from the UK Biocentre acquisition?

Azenta expects the acquisition to be dilutive to 2026 Adjusted EBITDA margin by ~35 basis points. According to Azenta, the dilution is pro forma for 2026, with anticipated accretion to 2027–2028 targets.

How will the UK Biocentre acquisition affect Azenta's European operations and capacity?

The acquisition establishes the UK Biocentre as a European operational hub to support customers across the region and complement the Griesheim, Germany biorepository. According to Azenta, this expands automated sample storage and integrated processing capabilities.

Will UK Biocentre keep its brand after the acquisition by Azenta (AZTA)?

Yes, UK Biocentre will continue to operate under its existing name after the acquisition. According to Azenta, the business will leverage Azenta's global platform while retaining its brand and operational identity.

When and how can investors listen to Azenta's call about the UK Biocentre acquisition?

Azenta will host a conference call and webcast on March 10, 2026 at 10:00 am ET. According to Azenta, the live webcast and presentation materials will be available via the Investor Relations section of its website, with a replay on March 11, 2026.